“showed a trend”

At week 24, subjects randomized to abatacept showed a trend toward improvement in mRSS (−8.6 p = 0.0625).

Blinded histopathological analyses were performed to validate the TME signature data, revealing that Cluster B showed a trend toward a non‐brisk classification ( p = 0.0625) and a lower percentage of immune cells ( p = 0.079).

Subjects receiving abatacept showed a trend toward improvement in mRSS at week 24 (−8.6 ± 7.5, p = 0.0625) while those in the placebo group did not (−2.3 ± 15, p = 0.75).

GHRHRs were more abundant in the border zones compared with their infarct zones in both GHRH‐A and placebo groups (73.5±8.1 versus 204.2±4.5 and 105.2±10.9 versus 196.3±2.3, respectively; P <0.0001 for both by Kruskal–Wallis test) ( Figure 6 B), and the GHRH‐A group showed a trend toward higher levels in the border zones ( P <0.0625 versus placebo by Wilcoxon rank test) than did the placebo group ( Figure 6 C).

Wilcoxon signed-rank testing (two-sided) showed a trend toward increasing convexity (median ΔKSI = +0.0157, p = 0.0625).

The frequency of classical (CD14 + ) monocytes showed a trend to decrease ( p = 0.0625) during the first 20 weeks after vaccination, while the frequency of non-classical monocytes, which are involved in T-cell stimulation and inflammatory cytokine release ( 38 ), showed a trend ( p = 0.0625) to increase over the same period of time.

As in the ITT population [ 4 , 13 ], patients in the biomarker subset receiving sunitinib had significantly longer PFS than those receiving IFN-α [median PFS 13.7 vs 5.1 months; hazard ratio 0.293 (95 % confidence interval or CI 0.129–0.665); P = 0.0021]; sunitinib patients in the biomarker subset also showed a trend for improved OS compared with IFN-α patients [median OS not reached vs 18.3 months; hazard ratio 0.509 (95 % CI 0.246–1.05); P = 0.0626].

12.9 months; p = 0.0143; HR = 1.52); (ii) Level Sum Score (LSS) predicted azacitidine response ( p = 0.0160; OR = 0.451) and the EQ-5D-5L index showed a trend ( p = 0.0627; OR = 0.522); (iii) up to 1432 longitudinally assessed EQ-5D-5L response/clinical parameter pairs revealed significant associations of EQ-5D-5L response parameters with haemoglobin level, transfusion dependence and hematologic improvement.

Action potential firing elicited by current injection showed a trend toward increased excitability [repeated measures ANOVA, main effect treatment: F (1, 39) = 3.672, p = 0.0627; time F (7,273) = 62.99, p < 0.0001; time × drug F (7,273) = 1.237, p = 0.2825; Figure 4F ], and reduced latency for AP firing [repeated measures ANOVA, main effect treatment: F (1, 39) = 3.435, p = 0.0714; time F (7, 273) = 70.88, p < 0.001; time × drug F (7, 273) = 0.9778, p = 0.4476; Figure 4G ].

Though not significant, 12-month-aged rats showed a trend toward longer strides than 3-month-aged rats (Fig. 1 b; t (20) = 1.97, p = 0.0627), indicating that overall stepping patterns are altered with age.

Multivariate regression analysis of predictors of longer than 8 days admission found that a higher removed gland weight correlated with longer length of hospitalization (95% confidence interval [CI] 0.07–1.5526; P =0.0308) and elevated alkaline phosphatase showed a trend toward significant correlation (95% CI −0.0002 to 0.0092; P =0.0628) for the same outcome.

WST assay revealed that TMAO-activated PBMCs showed a trend toward enhanced cytotoxic activity against AN3CA cells ( p = 0.0628; Fig. 6 H), while no significant effect was observed in HEC-1B cells ( p = 0.6398; Fig. 6 G).

The linear regression showed a trend with borderline significance between lifetime GAF and CYP2C19 metabolizer status association (ß = 3.5, 95% CI: −0.2–7.1; p = 0.063, Supplementary Table 1 ).

Compared with the 15% CP group, the serum P concentration was significantly higher in the 16.5% CP group ( p < 0.05), and the interaction of energy/protein level showed a trend to influence on P concentration ( p = 0.063).

Progression-free survival Univariate analysis of the whole collective and of the matched-pair group showed a trend towards better progression-free survival for the patients treated with CIRT (5.5 months vs. 3.9 months, p = 0.063; for the propensity score-matched group 5.7 months vs. 3.9 months, p = 0.085).

BMP4 and BMP6 also showed a trend of increased Ki67 mRNA (P = 0.063 and 0.052, respectively).

The radiation treatment group (group 2) showed a trend towards lower eNOS mRNA expression than the control group (group 1 vs group 2, p = 0.063 after post hoc test), but daily PDE5I treatment lessened this decrease (group 2 vs. group 3, p = 0.063 after post hoc test) ( Fig 2C ).

With increasing levels of EEO, the cecal Escherichia coli (linear, P = 0.085) count showed a trend in reduction, and the cecal lactic acid bacteria population tended to increase (linear, P = 0.063).

Pairwise comparison of pre- and post-operative HbA1c showed a trend toward HbA1c reduction at 3–6 months (7.68% to 7.56%, P = 0.063), with a significant HbA1c reduction in older subjects (7.62% to 7.39%, P = 0.004) and those with pre-operative HbA1c ≥8.0% (9.24% to 8.59%, P < 0.001) ( Table 1 and Figure 1 ).

In addition, patients with ileal disease at diagnosis showed a trend toward a higher risk of bleeding compared with those with colonic disease at diagnosis (HR: 6.58, 95%CI: 0.90-48.12; P = 0.063).

2 A and B ), although TetTox rats showed a trend for a reduction in ILPs ( t = 2.047, P = 0.063) (Fig. 2 C ).

Conversely, poor prognosis patients showed a trend towards higher levels of these two miRNAs than NET cell lines (miR‐17‐5p: H727 vs NENs, p = 0.063; BON‐1 vs NENs, p = 0.066; miR‐19a‐3p: H727 vs NENs, p = 0.085; BON‐1 vs NENs, p = 0.088).

The olfactory bulb pitch showed a trend of being correlated to cranial width (Χ 2 (1, n = 12) = −0.55, p = 0.063).

PELP1 hi cases also showed a trend towards worse BCSS (log-rank=3.446, p=0.063).

4E and F ) and showed a trend for a mediation of the effect of posterior hippocampal tau on memory performance [β = 0.09 (−0.005 to 0.184), P = 0.063].